These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973 [TBL] [Abstract][Full Text] [Related]
6. Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma. Strum S; Climans S; Purcell V; Black M; Winquist E; Ernst S J Cutan Med Surg; 2024; 28(5):453-457. PubMed ID: 39056376 [TBL] [Abstract][Full Text] [Related]
7. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444 [TBL] [Abstract][Full Text] [Related]
8. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360 [TBL] [Abstract][Full Text] [Related]
9. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M Front Oncol; 2021; 11():686308. PubMed ID: 34820323 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma. De Falco V; Napolitano S; Franco R; Zito Marino F; Formisano L; Esposito D; Suarato G; Napolitano R; Esposito A; Caraglia F; Giugliano MC; Cioli E; Famiglietti V; Bianco R; Argenziano G; Ronchi A; Ciardiello D; Nardone V; D'Ippolito E; Del Tufo S; Ciardiello F; Troiani T Oncoimmunology; 2024; 13(1):2388315. PubMed ID: 39206096 [TBL] [Abstract][Full Text] [Related]
11. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol. Verkerk K; Geurts BS; Zeverijn LJ; van der Noort V; Verheul HMW; Haanen JBAG; van der Veldt AAM; Eskens FALM; Aarts MJB; van Herpen CML; Jalving M; Gietema JA; Devriese LA; Labots M; Barjesteh van Waalwijk van Doorn-Khosrovani S; Smit EF; Bloemendal HJ Lancet Reg Health Eur; 2024 Apr; 39():100875. PubMed ID: 38464480 [TBL] [Abstract][Full Text] [Related]
12. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660 [TBL] [Abstract][Full Text] [Related]
14. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab). Challapalli A; Stewart G; Shaw H; Davies PJ; Lopez-Baez JC; Ottley EC; Kelly S Front Immunol; 2024; 15():1408667. PubMed ID: 39072317 [TBL] [Abstract][Full Text] [Related]
15. Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices. Ge W; Wu N; Chen CI; Inocencio TJ; LaFontaine PR; Seebach F; Fury M; Harnett J; Ruiz ES Cancer Manag Res; 2024; 16():841-854. PubMed ID: 39050978 [TBL] [Abstract][Full Text] [Related]
16. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center. Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176 [TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience. Hasmat S; Howle JR; Carlino MS; Sundaresan P; Veness MJ ANZ J Surg; 2023 Jan; 93(1-2):235-241. PubMed ID: 36567642 [TBL] [Abstract][Full Text] [Related]
20. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives. Mager L; Gardeen S; Carr DR; Shahwan KT Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]